Bevacizumab Weight-Based Dosing Regimens
Bevacizumab dosing varies by indication, with FDA-approved regimens ranging from 5 mg/kg to 15 mg/kg administered intravenously every 2-3 weeks depending on the specific cancer type and treatment setting. 1
FDA-Approved Dosing by Indication
Metastatic Colorectal Cancer
- 5 mg/kg IV every 2 weeks when combined with bolus-IFL chemotherapy 1
- 10 mg/kg IV every 2 weeks when combined with FOLFOX4 1
- 5 mg/kg IV every 2 weeks OR 7.5 mg/kg IV every 3 weeks when combined with fluoropyrimidine-irinotecan or fluoropyrimidine-oxaliplatin-based chemotherapy in patients who progressed on first-line bevacizumab-containing regimens 1
Non-Squamous Non-Small Cell Lung Cancer
- 15 mg/kg IV every 3 weeks in combination with carboplatin and paclitaxel 1
Recurrent Glioblastoma
- 10 mg/kg IV every 2 weeks as monotherapy 1
Metastatic Renal Cell Carcinoma
- 10 mg/kg IV every 2 weeks in combination with interferon alfa 1
Cervical Cancer (Persistent, Recurrent, or Metastatic)
- 15 mg/kg IV every 3 weeks in combination with paclitaxel and cisplatin, or with paclitaxel and topotecan 1
Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Stage III/IV Following Initial Surgical Resection:
- 15 mg/kg IV every 3 weeks with carboplatin and paclitaxel for up to 6 cycles, followed by bevacizumab 15 mg/kg every 3 weeks as single agent for total of up to 22 cycles or until disease progression 1
Platinum-Resistant Recurrent Disease:
- 10 mg/kg IV every 2 weeks with paclitaxel, pegylated liposomal doxorubicin, or weekly topotecan 1
- 15 mg/kg IV every 3 weeks with topotecan given every 3 weeks 1
Platinum-Sensitive Recurrent Disease:
- 15 mg/kg IV every 3 weeks with carboplatin and paclitaxel for 6-8 cycles, followed by bevacizumab 15 mg/kg every 3 weeks as single agent until progression 1
- 15 mg/kg IV every 3 weeks with carboplatin and gemcitabine for 6-10 cycles, followed by bevacizumab 15 mg/kg every 3 weeks as single agent until progression 1
Hepatocellular Carcinoma
- 15 mg/kg IV every 3 weeks after administration of 1,200 mg atezolizumab on the same day, until disease progression or unacceptable toxicity 1
NCCN Guideline Dosing Recommendations
The NCCN guidelines provide additional context for ovarian cancer dosing based on clinical trial data:
For newly diagnosed ovarian cancer (per ICON-7 and GOG-218 trials):
- 7.5 mg/kg IV every 3 weeks with paclitaxel 175 mg/m² and carboplatin AUC 5-6 for 5-6 cycles, continuing bevacizumab for up to 12 additional cycles (Category 2B) 2
- 15 mg/kg IV every 3 weeks starting cycle 2, with paclitaxel 175 mg/m² and carboplatin AUC 6 for 6 cycles, continuing bevacizumab for up to 22 cycles (Category 2B) 2
For colon cancer:
Critical Administration Requirements
Surgical Timing:
- Withhold bevacizumab for at least 28 days before elective surgery 1
- Do not administer for at least 28 days following major surgery and until adequate wound healing is confirmed 1
Infusion Administration:
- Administer as IV infusion over 30-90 minutes 2, 1
- Dilute in 100 mL of 0.9% Sodium Chloride Injection only—never use dextrose solutions 1
- Bevacizumab may be safely administered at 0.5 mg/kg/min (5 mg/kg over 10 minutes, 7.5 mg/kg over 15 minutes) 3
Pharmacokinetic Considerations
Bevacizumab exhibits linear pharmacokinetics between 0.3-10 mg/kg every 2-3 weeks 4. The terminal half-life is approximately 20 days, with steady state reached in approximately 100 days 4. Clearance is 26% faster in men than women, though no dose adjustment is currently recommended based on gender, age, or renal function 4, 5.
Key Clinical Caveats
No dose reductions are recommended for bevacizumab—only withholding or permanent discontinuation based on specific adverse reactions 1. The optimal dose remains debated, as dose-effect relationships have not been definitively proven in vivo 6. However, the FDA-approved dosing regimens above represent the evidence-based standards established through pivotal clinical trials demonstrating survival benefits 1.